• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Who We Are

The International Alliance of ALS/MND Associations was founded in 1992. Today, we bring together more than 80 member organizations across the globe, united by a single vision: a world free of ALS/MND.

Everything we do is centred around the fundamental rights of people affected by ALS/MND — the belief that where you live should not determine the quality of care, support, and respect you receive.

We work alongside our members to raise awareness, coordinate research, advocate for equitable access to care and therapies, and ensure that under-represented communities are not left behind. Our global reach means that knowledge, tools, and best practices developed anywhere in the world can benefit people everywhere.

What Guides Us

Our Vision

A world free of ALS/MND

Our Aspiration

To drive global collaboration

Our Reach

We work globally, serving the entire ALS/MND community — people living with the disease, caregivers, clinicians, researchers, and the organizations that support them.

Our Purpose

Everything we do is oriented around one purpose: accelerating progress on the Fundamental Rights of people affected by ALS/MND, everywhere in the world.

Our Strategic Priorities

The Alliance’s 2026–2028 Strategy sets out six priorities that will guide our work over the coming years.

Bring focus to quality of life

We advocate more effectively to improve outcomes by understanding what people living with ALS/MND (PALS) and their community identify as important.

Include under-represented communities

By working alongside under-represented communities, we ensure meaningful inclusion across the globe so geography does not dictate destiny.

Increase awareness of ALS/MND

By raising awareness of ALS/MND and the Alliance, we strengthen our advocacy efforts at the global level, which supports our members at the local level.

Facilitate research coordination

By bringing people together and facilitating research coordination across the globe, we deepen our understanding of ALS/MND and accelerate research.

Leverage collective capacity

By coordinating with our members and partnering in strategic international collaborations, we leverage collective knowledge and resources — positioning the Alliance as a trusted source of evidence-based information, best practices, and tools.

Grow the community

By identifying and inviting ALS/MND organizations not yet part of the Alliance, and by supporting the creation and development of new organizations, we expand the community working toward a world free of ALS/MND.

Learn More

Alliance Strategy 2026–2028

Our three-year roadmap for driving global collaboration toward a world free of ALS/MND.

Read the Strategy →

Annual Report 2024–2025

A review of the Alliance’s work and impact over the past year.

Read the Annual Report →

Primary Sidebar

About

  • Who We Are
  • Board of Trustees
  • Councils, Forums & Committees
    • PALS and CALS Advisory Council
    • Scientific Advisory Council
    • Advocacy and Public Policy Forum
    • Research Directors Forum
    • Governance Committee
    • Finance Committee
  • Staff
  • History
  • Newsletter Archive
    • Meetings
  • Awards

  • Claudia Cominetti, Italy

    Claudia Cominetti, Italy

  • Jean

    Jean
    jean

  • Erwin Coppejans, Belgium

    Erwin Coppejans, Belgium

  • Wilfried Leusing, Germany

    Wilfried Leusing, Germany

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Eddy LeFrançois, Canada

    Eddy LeFrançois, Canada

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Timmy, Belgium

    Timmy, Belgium

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Mike Rannie, Canada

    Mike Rannie, Canada

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Dick Dayton, USA

    Dick Dayton, USA

  • Len Johnrose, England

    Len Johnrose, England

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Glen Elison, USA

    Glen Elison, USA

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Angie Bordaen, Belgium

    Angie Bordaen, Belgium

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Jack Buzby, USA

    Jack Buzby, USA

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Emilienne Verhaegen, Belgium

    Emilienne Verhaegen, Belgium

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Manuel Arn, Switzerland

    Manuel Arn, Switzerland

  • Animesh Kumar, India

    Animesh Kumar, India

  • Conny van der Meijden, Netherlands

    Conny van der Meijden, Netherlands

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • John Russo, USA

    John Russo, USA
    final3878

  • Ali Var, Turkey

    Ali Var, Turkey

  • Michael Lee, Australia

    Michael Lee, Australia

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Anna Barrow, UK

    Anna Barrow, UK

  • David Bishop, UK

    David Bishop, UK

  • Steve

    Steve

  • Rob Tison, USA

    Rob Tison, USA

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Purningam Jacob, India

    Purningam Jacob, India

  • Aida Trzmiel de Guterman, Argentina

    Aida Trzmiel de Guterman, Argentina

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login